Nebenwirkungen · Wegovy
Wegovy 0.25 mg solution for injection in pre-filled pen Wegovy 0.5 mg solution for injection in pre-filled pen Wegovy 1 mg solution for injection in pre-filled pen Wegovy 1.7 mg solution for injection in pre-filled pen Wegovy 2.4 mg solution for injection in pre-filled pen Wegovy 7.2 mg solution for injection in pre-filled pen Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen Wegovy 1 mg FlexTouch solution for injection in pre-filled pen Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.25 mg solution for injection in pre-filled syringe Wegovy 0.5 mg solution for injection in pre-filled syringe Wegovy 1 mg solution for injection in pre-filled syringe Wegovy 1.7 mg solution for injection in pre-filled syringe Wegovy 2.4 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 13
HOS-147331 · Präparat HOS-099634
In a clinical trial conducted in adolescents of 12 years to below 18 years of age with obesity or overweight with at least one weight-related comorbidity, 133 patients were exposed to semaglutide. The trial duration was 68 weeks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage af37df033686b11b24b0e6c7c3a24ee70fe0a145a13ddc6e1a171608f4625abd · Zeichen 11785–12014 im Abschnitt